Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  uniQure  /  UniQure IPO

Ontvang nu dagelijks onze kooptips!

word abonnee

uniQure« Terug naar discussie overzicht

UniQure IPO

341 Posts
Pagina: «« 1 2 3 4 5 6 ... 18 »» | Laatste | Omlaag ↓
  5. [verwijderd] 2 januari 2014 23:31
    Stefano ik snap je beredenering, alleen kan het niet herleiden.
    Harry spreekt over een marktcap van 533 miljoen dollar; bij om en nabij 70 miljoen uitstaande aandelen maal 7,50 dollar.

    Tot nader order denk ik dat 7,50 per aandeel te billijken valt.
    Mochten we 3 aandelen in moeten leveren waarvoor we er 1 terug krijgen van 2,50 bijvoorbeeld,
    ook dan heb ik wel vertrouwen in markttoetreding Glybera in de VS en fase verbeteringen in de pijplijn in 2014.
    Des te minder aandelen des te groter de koerspotentie bij positieve ontwikkelingen.

    De table of contents vallen overigens niet mee..
    Alles wat ik lees kan ik op verschillende manieren interpreteren.
  7. forum rang 10 DeZwarteRidder 2 januari 2014 23:32
    quote:

    stefano 1 schreef op 2 januari 2014 23:23:

    Dus weer geen kip met goude eieren jammer was ook te mooi om waar te zijn
    Dit zat er dik in, ik heb nog gewaarschuwd, die prijs kan natuurlijk nog veel lager worden als er te weinig belangstelling is.

    Glybera is een hopeloos geval, daar krijg je geen investeerders mee naar huis.
  8. forum rang 10 DeZwarteRidder 2 januari 2014 23:34
    quote:

    Uperdepup schreef op 2 januari 2014 23:31:

    Stefano ik snap je beredenering, alleen kan het niet herleiden.
    Harry spreekt over een marktcap van 533 miljoen dollar; bij om en nabij 70 miljoen uitstaande aandelen maal 7,50 dollar.

    Tot nader order denk ik dat 7,50 per aandeel te billijken valt.
    Mochten we 3 aandelen in moeten leveren waarvoor we er 1 terug krijgen van 2,50 bijvoorbeeld,
    ook dan heb ik wel vertrouwen in markttoetreding Glybera in de VS en fase verbeteringen in de pijplijn in 2014.
    Des te minder aandelen des te groter de koerspotentie bij positieve ontwikkelingen.
    Ik hoop dat de IPO doorgaat, dan ga ik gelijk short; kat in 't bakkie!!
  11. forum rang 10 DeZwarteRidder 2 januari 2014 23:46
    Ze verliezen ca 20,5 miljoen per 9 maanden, dat is ca 27 miljoen op jaarbasis.
    Dus binnen ruim een jaar is al hun huidige kasgeld weer opgebrand....!!

    Die IPO gaat dus zeker door (tegen iedere prijs), want anders gaan ze failliet.

    En tot overmaat van ramp is er nog steeds geen echte omzet geboekt.
  13. forum rang 10 DeZwarteRidder 2 januari 2014 23:53
    Risks Related to Our Financial Position and Need for Additional Capital

    We have incurred significant losses to date, expect to incur losses over the next several years and may never achieve or maintain profitability.

    We have incurred significant losses to date. We had a net loss of €20.4 million in the first nine months of 2013, €14.7 million in 2012 and €17.3 million in 2011. As of September 30, 2013, we had an accumulated deficit of €138.0 million. To date, we have financed our operations primarily through the sale of equity securities and convertible debt and, to a lesser extent, through milestone payments, subsidies and grants from governmental agencies and fees for services. We have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical trials. Our product, Glybera, received marketing approval under exceptional circumstances from the European Commission in October 2012. We plan in the future to apply for marketing approval for Glybera in the United States and other countries and expect that we will be required to conduct one or more additional clinical trials of Glybera. We are still in the early stages of development of the other product candidates in our pipeline. We expect to continue to incur significant expenses and losses over the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:

    •
    complete the EMA-mandated post-approval clinical trial of Glybera and implementation of an LPLD patient registry;

    •
    conduct a confirmatory clinical trial of Glybera, either as part of the EMA-mandated post-approval clinical trial or separately, to obtain data needed to file a BLA for Glybera with the FDA;

    •
    seek marketing approval of Glybera in the United States and other countries;

    •
    initiate a Phase I/II clinical trial of AMT-060 for hemophilia B in collaboration with Chiesi;

    •
    advance the clinical development of our other product candidates, most of which are at early stages of development, and seek to discover and develop additional product candidates;

    •
    seek marketing approval for any product candidates that successfully complete clinical trials;

    •
    establish a sales, marketing and medical affairs infrastructure in the United States;

    •
    continue the build-out of our manufacturing facility in Lexington, Massachusetts to expand our manufacturing capabilities for Glybera and our pipeline of product candidates;

    •
    maintain, expand and protect our intellectual property portfolio, including in-licensing additional intellectual property rights from third parties;

    •
    hire additional personnel, particularly in our manufacturing, research, clinical development, medical affairs, commercial and quality control groups; and

    •
    add operational, financial and management information systems and related finance and compliance personnel necessary to operate as a public company.

    We are only in the preliminary stages of most of these activities. We and our collaborators may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability.
  15. forum rang 10 DeZwarteRidder 2 januari 2014 23:54
    Our financial results will substantially depend on the commercial success of sales of Glybera.

    We anticipate that our collaborator Chiesi will commercially launch Glybera in the European Union in the first half of 2014 and that revenues from sales of Glybera will be one of the principal sources of funds for our business for at least the next several years. Because our business is currently dependent on Glybera, failure to achieve anticipated revenues from this product would have an adverse effect on our results of operations and cause the value of our ordinary shares to decline. A number of factors, some of which are out of our control, may adversely affect the commercial success of Glybera, including the following:

    •
    our collaborator Chiesi may not successfully commercialize Glybera in the European Union and other specified countries in the Chiesi territory;

    •
    the post-approval requirements imposed by the EMA in connection with Glybera's approval under exceptional circumstances may be costly or may eventually lead to withdrawal of approval;

    •
    we may never be able to obtain marketing approval for Glybera in the United States or other countries;

    •
    Glybera may fail to achieve market acceptance by physicians, patients, third party payors and others in the medical community;

    •
    other alternative treatments for LPLD may be developed and gain commercial acceptance, eroding Glybera's market share;

    •
    the limited label we have received for Glybera in the European Union may limit our addressable market, and other regulatory agencies may approve Glybera only with a similarly limited label;

    •
    we may be unable to establish or maintain sales, marketing and medical affairs capabilities for the commercialization of Glybera in the United States, even if we receive FDA approval; and

    •
    coverage, pricing and reimbursement levels may be lower than we expect.

    Even if our commercialization of Glybera or other product candidates for which we obtain marketing approval is successful, we may not be financially successful due to our obligations to third parties.
  20. forum rang 10 DeZwarteRidder 3 januari 2014 00:02
    Revenues

    License revenues of €0.2 million in the nine months ended September 30, 2013, related to the amortization of the up front payment received from Chiesi in July 2013.

    Collaboration revenues of €1.8 million in the nine months ended September 30, 2013 consisted mainly of reimbursements of covered expenses by Chiesi under our co-development agreement for hemophilia B, together with revenue from Institut Pasteur relating to our collaboration with them on Sanfilippo B. We had no revenues in the nine months ended September 30, 2012.

    Cost of Goods Sold

    Cost of goods sold of €0.8 million in the nine months ended September 30, 2013 consisted of the recognition of a repayment obligation to the Dutch government with respect to a portion of a technical development loan. This repayment obligation was triggered by our entitlement to receive during the second quarter 2013 a €2.0 million upfront payment from Chiesi in relation to our Glybera program. We had no cost of goods sold in the first nine months of 2012.
341 Posts
Pagina: «« 1 2 3 4 5 6 ... 18 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 882,63 0,00%
EUR/USD 1,0728 +0,30%
FTSE 100 8.139,83 +0,75%
Germany40^ 18.177,90 +0,09%
Gold spot 2.331,50 -0,28%
NY-Nasdaq Composite 15.927,90 +2,03%

Stijgers

EBUSCO...
+9,33%
NX FIL...
+8,77%
ASMI
+7,26%
Alfen ...
+5,89%
PostNL
+3,82%

Dalers

SIGNIF...
-11,28%
Wereld...
-7,62%
AMG Cr...
-5,77%
IMCD
-4,90%
ABN AM...
-4,19%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!